243 related articles for article (PubMed ID: 26974204)
41. SPHK1 promotes metastasis of thyroid carcinoma through activation of the S1P/S1PR3/Notch signaling pathway.
Zhao Z; Ma J; Hu B; Zhang Y; Wang S
Exp Ther Med; 2018 Jun; 15(6):5007-5016. PubMed ID: 29805524
[TBL] [Abstract][Full Text] [Related]
42. Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy.
Martínez-Sáez O; Gajate Borau P; Alonso-Gordoa T; Molina-Cerrillo J; Grande E
Crit Rev Oncol Hematol; 2017 Mar; 111():117-123. PubMed ID: 28259286
[TBL] [Abstract][Full Text] [Related]
43. Allosteric inhibition of HIF-2α as a novel therapy for clear cell renal cell carcinoma.
Yu Y; Yu Q; Zhang X
Drug Discov Today; 2019 Dec; 24(12):2332-2340. PubMed ID: 31541711
[TBL] [Abstract][Full Text] [Related]
44. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer.
Smith K; Gunaratnam L; Morley M; Franovic A; Mekhail K; Lee S
Cancer Res; 2005 Jun; 65(12):5221-30. PubMed ID: 15958567
[TBL] [Abstract][Full Text] [Related]
45. Hypoxia-inducible factor-2α stabilizes the von Hippel-Lindau (VHL) disease suppressor, Myb-related protein 2.
Okumura F; Joo-Okumura A; Nakatsukasa K; Kamura T
PLoS One; 2017; 12(4):e0175593. PubMed ID: 28394947
[TBL] [Abstract][Full Text] [Related]
46. Overexpression of HIF-2α in pancreatic β cells does not alter glucose homeostasis.
Brunt JJ; Shi SY; Schroer SA; Sivasubramaniyam T; Cai EP; Woo M
Islets; 2014; 6(5-6):e1006075. PubMed ID: 25833250
[TBL] [Abstract][Full Text] [Related]
47. Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma.
Grabmaier K; A de Weijert MC; Verhaegh GW; Schalken JA; Oosterwijk E
Oncogene; 2004 Jul; 23(33):5624-31. PubMed ID: 15184875
[TBL] [Abstract][Full Text] [Related]
48. Follistatin-like protein 1 plays a tumor suppressor role in clear-cell renal cell carcinoma.
Liu Y; Tan X; Liu W; Chen X; Hou X; Shen D; Ding Y; Yin J; Wang L; Zhang H; Yu Y; Hou J; Thompson TC; Cao G
Chin J Cancer; 2018 Jan; 37(1):2. PubMed ID: 29357946
[TBL] [Abstract][Full Text] [Related]
49. Expression of hypoxia inducible factor-1alpha and 2alpha in genetically distinct early renal cortical tumors.
Kim CM; Vocke C; Torres-Cabala C; Yang Y; Schmidt L; Walther M; Linehan WM
J Urol; 2006 May; 175(5):1908-14. PubMed ID: 16600797
[TBL] [Abstract][Full Text] [Related]
50. Sphingosine kinase 1 overexpression contributes to sunitinib resistance in clear cell renal cell carcinoma.
Xu Y; Dong B; Wang J; Zhang J; Xue W; Huang Y
Oncoimmunology; 2018; 7(12):e1502130. PubMed ID: 30524898
[TBL] [Abstract][Full Text] [Related]
51. SPHK1 Is a Novel Target of Metformin in Ovarian Cancer.
Hart PC; Chiyoda T; Liu X; Weigert M; Curtis M; Chiang CY; Loth R; Lastra R; McGregor SM; Locasale JW; Lengyel E; Romero IL
Mol Cancer Res; 2019 Apr; 17(4):870-881. PubMed ID: 30655321
[TBL] [Abstract][Full Text] [Related]
52. The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma.
Casagrande S; Ruf M; Rechsteiner M; Morra L; Brun-Schmid S; von Teichman A; Krek W; Schraml P; Moch H
J Pathol; 2013 Mar; 229(4):525-34. PubMed ID: 23007793
[TBL] [Abstract][Full Text] [Related]
53. Poor prognosis and advanced clinicopathological features of clear cell renal cell carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia inducible factor-2α.
Kroeger N; Seligson DB; Signoretti S; Yu H; Magyar CE; Huang J; Belldegrun AS; Pantuck AJ
Eur J Cancer; 2014 May; 50(8):1531-40. PubMed ID: 24565854
[TBL] [Abstract][Full Text] [Related]
54. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU
Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362
[TBL] [Abstract][Full Text] [Related]
55. Targeting renal cell carcinoma with a HIF-2 antagonist.
Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
[TBL] [Abstract][Full Text] [Related]
56. VHL and HIF signalling in renal cell carcinogenesis.
Baldewijns MM; van Vlodrop IJ; Vermeulen PB; Soetekouw PM; van Engeland M; de Bruïne AP
J Pathol; 2010 Jun; 221(2):125-38. PubMed ID: 20225241
[TBL] [Abstract][Full Text] [Related]
57. HER2 regulates HIF-2α and drives an increased hypoxic response in breast cancer.
Jarman EJ; Ward C; Turnbull AK; Martinez-Perez C; Meehan J; Xintaropoulou C; Sims AH; Langdon SP
Breast Cancer Res; 2019 Jan; 21(1):10. PubMed ID: 30670058
[TBL] [Abstract][Full Text] [Related]
58. HIF-2α regulates CD44 to promote cancer stem cell activation in triple-negative breast cancer
Bai J; Chen WB; Zhang XY; Kang XN; Jin LJ; Zhang H; Wang ZY
World J Stem Cells; 2020 Jan; 12(1):87-99. PubMed ID: 32110277
[TBL] [Abstract][Full Text] [Related]
59. Vhl deletion in renal epithelia causes HIF-1α-dependent, HIF-2α-independent angiogenesis and constitutive diuresis.
Schönenberger D; Rajski M; Harlander S; Frew IJ
Oncotarget; 2016 Sep; 7(38):60971-60985. PubMed ID: 27528422
[TBL] [Abstract][Full Text] [Related]
60. Differential effects of HIF-α isoforms on apoptosis in renal carcinoma cell lines.
Doonachar A; Gallo MD; Doukas D; Pasricha R; Lantsberg I; Schoenfeld AR
Cancer Cell Int; 2015; 15():23. PubMed ID: 25729330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
